Improving Patients’ Well-Being and Psoriasis-Related Work Productivity With Tildrakizumab: 52-Week Interim Results From the Phase IV Real-World Positive Study in Patients With Moderate-to-Severe Plaque Psoriasis

Speaker(s)

Augustin M1, Sommer R1, Reguiai Z2, Gerdes S3, Daudén E4, Weger W5, Maul JT6, Laws P7, Naldi L8, Ghislain PD9, de Jong E10, Mburu S11, Koscielny V12, Massana Montejo E12, Kasujee I12, Mrowietz U13
1Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Hamburg, Germany, 2Dermatology Department, Polyclinic Courlancy-Bezannes, Reims, Marne, France, 3Center for Inflammatory Skin Diseases, Department of Dermatology, Venereology and Allergology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein, Germany, 4La Princesa University Hospital, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Madrid, Spain, 5Department of Dermatology and Venereology, Medical University of Graz, Graz, Styria, Austria, 6Department of Dermatology, University Hospital Zurich; Faculty of Medicine, University of Zurich, Zurich, Zurich, Switzerland, 7Leeds Teaching Hospitals NHS Trust, Leeds, Yorkshire, UK, 8Division of Dermatology, San Bortolo Hospital, Vicenza, Veneto, Italy, 9Department of Dermatology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Brussels, Belgium, 10Department of Dermatology, Radboud University Medical Center (Radboudumc), Nijmegen, Gelderland, Netherlands, 11International Federation of Psoriasis Associations, Stockholm, Stockholm, Sweden, 12Almirall, Barcelona, Spain, 13Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein, Germany

Presentation Documents

OBJECTIVES: Chronic diseases can affect work productivity by impacting on well-being. The objective was to assess the effect of tildrakizumab treatment on the overall well-being and work productivity of moderate-to-severe psoriasis patients in the real-world setting.

METHODS: POSITIVE is a 24-month real-world study in adults with moderate-to-severe chronic plaque psoriasis treated with tildrakizumab. Well-being was assessed through the 5-item WHO Well-being Index questionnaire (WHO-5; total score ranging 0-100 [0=absence of well-being, 100=maximal well-being]; threshold for a clinically relevant change=10 points). Work productivity was assessed through the Work Productivity and Activity Impairment (WPAI) questionnaire, which yields 4 scores (%): work time missed (absenteeism), impairment at work (presenteeism), work productivity loss, and activity impairment. Here, we report 52-week (W) interim data (observed cases).

RESULTS: 400 patients were included (63.3% male, mean [95% CI] age 46.5 [45.1-48.0] years). Mean Psoriasis Area and Severity Index decreased from 13.1 (12.3-13.8) at baseline to 1.7 (1.4, 1.9) at W28 and 1.5 (1.2-1.7) at W52 (p<0.0001, both). Mean WHO-5 score increased from 53.8 (51.6-56.1) at baseline to 66.0 (63.7-68.4) at W28 and 65.7 (63.0-68.4) at W52 (p<0.0001, both). Concerning WPAI domain scores, mean percent absenteeism decreased from 8.4 (5.5-11.3) at baseline to 1.8 (0.3-3.4) at W28 (p<0.001) and 4.2 (1.5-6.9) at W52; mean percent presenteeism decreased from 22.3 (18.9-25.7) at baseline to 6.2 (4.0-8.5) at W28 and 4.7 (2.8-6.6) at W52 (p<0.0001, both); mean percent work productivity loss decreased from 25.2 (21.6-28.8) at baseline to 7.0 (4.5-9.4) at W28 and 7.3 (4.8-9.8) at W52 (p<0.0001, both); and mean percent activity impairment decreased from 32.8 (29.8-35.8) at baseline to 11.4 (8.8-14.0) at W28 and 11.0 (8.1-13.9) at W52 (p<0.0001, both).

CONCLUSIONS: In a real-world setting, tildrakizumab significantly improved patients’ well-being and psoriasis-related work productivity in moderate-to-severe psoriasis patients after 28 weeks, and the improvement was maintained through W52.

Code

PCR110

Topic

Patient-Centered Research, Study Approaches

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes, Prospective Observational Studies

Disease

Biologics & Biosimilars, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)